A Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris for 12 Weeks
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Tazarotene (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions
- Sponsors Dr Reddys Laboratories
- 31 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 31 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Feb 2018.
- 17 Nov 2017 New trial record